Anti-SMN antibody-positive patients with RMDs exhibit a higher prevalence of ILD, PAH, myositis, and SSc-related symptoms compared with anti-SMN antibody-negative patients [8, 9, 26]. Here, SMN1 is linked to systemic sclerosis.